<DOC>
	<DOC>NCT01561950</DOC>
	<brief_summary>This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with clopidogrel (PlavixÂ®).</brief_summary>
	<brief_title>Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>PT/PTT within normal laboratory range (e.g., PT: 9.412.0) Platelet count within normal laboratory range The receipt of any investigational drug within 1 month prior to this trial Use of anticoagulation therapydefined as vitamin K antagonists, platelet antagonists, heparin (or low molecular weight heparin), aspirin or NSAIDs (nonsteroidal antiinflammatory drug) within 30 days prior to trial AfricanAmerican race Weight above or equal to 160 kg</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>